A single injection of a small peptide into a mouse leg muscle set off growth that lasted three months. The same peptide pointed at a signaling fat as the engine behind that growth. In old mice, that signal never showed up.
The peptide is MID-35, a 16-amino-acid molecule built to block myostatin ↗, the protein the body uses as a brake on muscle size. Turn myostatin down and muscle grows. A team reported the work on May 26 in ACS Pharmacology and Translational Science ↗.
What makes MID-35 unusual is how it is built. It is a D-peptide, which means its amino acids are the mirror-image form of the ones cells normally use. Mirror-image peptides are hard for the body's enzymes to chew up, so they survive far longer than ordinary peptides. One shot into the tibialis anterior, the long muscle at the front of the shin, carried a dose of 2 nanomoles. That was enough.
The muscle responded fast. Within three days, genes that mark muscle building (Pax7, Myod1, Myog) climbed, and two genes that drive muscle wasting (Trim63, Fbxo32) dropped. Actual weight gain took longer, showing up around day 14. Then it held. The enlarged muscle stayed enlarged for 12 weeks after that single injection. For a peptide, a three-month effect from one dose is unusual.
The bigger players in this field are antibodies, not peptides. Bimagrumab, an antibody against the ActRIIB receptor now studied in obesity, and trevogrumab, a Regeneron antibody aimed at myostatin itself, both block the same pathway from outside the cell and require repeated dosing. A small peptide that does the job from one intramuscular shot, and holds for 12 weeks, is a different delivery bet.
The mechanism is the paper's real contribution. The team tracked sphingosine 1-phosphate, or S1P, a fat-derived signaling molecule that helps wake up satellite cells, the stem cells that sit beside muscle fibers and rebuild them. In young and adult mice, S1P rose on day 3, exactly when the muscle-building genes switched on. New centralized nuclei and Pax7-positive signals in the treated muscle backed up the idea that satellite cells had been called into action.
In aged mice, that day-3 rise did not happen. Aging changed how the muscle handled the lipid, and the spike that accompanied the young and adult response was gone. That matters because aged muscle is exactly where a myostatin blocker would be aimed. Older people lose muscle, a condition called sarcopenia, and the satellite-cell repair machinery is already sluggish. A drug that leans on S1P to recruit those cells may find the lever missing in the muscle that needs it most.
None of this is a human result. It is mouse shin muscle, one peptide, one lab. MID-35 also blocks GDF-11 and activin A, two close relatives of myostatin that all signal through the same receptor, ActRIIB, so the growth is not myostatin alone. And the paper does not claim that aged muscle failed to grow. It claims the proposed S1P mechanism was absent there, which is the more honest finding, because it tells the next experiment where to look.
On peptidemodel, myostatin sits behind a small cluster of experimental muscle-growth peptides. A follistatin fragment ↗ hits the same four-target set MID-35 does: myostatin, GDF-11, activin A, and ActRIIB. A myostatin prodomain peptide ↗ and the follistatin-derived DF-3 ↗ block myostatin more narrowly. MID-35 is not hosted, but it lands in the same neighborhood: short, synthetic, aimed at the body's muscle brake, and now carrying a mechanism that bends with age. ↯